UBI集團訊息
UBP announces UB-421 research data at Cold Spring Harbor Laboratory Conference on HIV/AIDS Research
The conference: HIV/AIDS Research: Its History & Future, was held from 13th to 16th in October. Leading experts in the HIV field including Dr. Robert Gallo, the first scientist confirmed HIV was the cause of AIDS; Dr. Francoise Barrè-Sinoussi, the Nobel Laureate in Physiology or Medicine in 2008 from Institut Pasteur; Dr. Harold Varmus, the Nobel Laureate in Physiology or Medicine in 1989; Dr. Anthony Fauci, the director of the National Institute of Allergy and Infectious Diseases (NIAID); Dr. Flossie Wong Staal, one of the scientists to clarify HIV molecular structure; Dr. Emilio Emini, dean of research and development affairs from Bill & Melinda Gates Foundation; Dr. Daria Hazuda, the project leader in AIDS drug research from Merck; Dr. John Martin, Chief Executive Officer from Gilead, Dr. Marty Clair from ViiV Healthcare and Dr. David Baltimore, the Nobel Laureate in Physiology or Medicine in 1975 were invited to share their expertise.The conference addressed topics of the animal retrovirus, the source of virus, molecular biology, immunology, preventive medicine, antiretroviral therapy, HIV treatment mechanism and concluded with a discussion on the future outlook of HIV treatment.
Dr. Flossie Wong Staal presented her historical data in HIV structural and functional studyies and the discovery in the UB-421 clinical trial in collaboration with the UBI group. Over a 16-week treatment period, HIV/AIDS patients with UB-421 monotherapy reached 100% inhibition to HIV viruses, and displayed a tendency of reservoir reduction, displaying superior efficacy to highly active antiretroviral therapy (HAART) and current monoclonal antibody drug treatments. The resultsindicated that UB-421 could potentially become a candidate drug in substitution or combination treatment of HAART for AIDS cure. Meanwhile, the UB-421 phase II clinical trial showed a reduction in the number of T regulatory cells and increase in the number of CD8 T cells, indicating the T cell immunity of HIV patients could be potentially restored, which is one of the key mechanisms for HIV functional cure.
Currently, there is no monotherapy that could efficiently substitute HAART for HIV/AIDS treatment. UBP is proceeding to synchronize the UB-421 phase III clinical trial in Taiwan, China and the United States. UBP will subsequently submit the qualifying criteria application to the U.S. FDA for breakthrough therapy and collaborate with Dr. Anthony Fauci in NIAID further in studying UB-421 as a functional cure.
About UBP (6471)
United Biopharma Inc. was established in September 2013 as a spinoff from United Biomedical, Inc., Asia, and is strategically partnering with Formosa Plastics Group. UBP has an integrated monoclonal antibody drug development platform, and focuses on development, manufacture, and marketing of innovative monoclonal antibody drugs and biosimilars. With a spirit of “innovation and practicality,” UBP is dedicated to addressing unmet medical needs to improvethe health of mankind.
About UB-421
UB-421 is a humanized monoclonal antibody, which recognizes and binds to domain 1 of the CD4 molecule, the same site for HIV virus binding. This direct competition for binding to CD4 is termed competitive inhibition and effectively blocks the entry of HIV virus into CD4+ cells, thus inhibiting HIV infection. Competitive inhibition also prevents generation of drug resistance resulting from the mutation of the HIV virus.
UB-421 is an innovative antibody drug developed solely by UBP. UBP has received the Technology Development grants from Taiwan government four times, won the Silver Prize in 2012 and Gold Prize in 2014 of the Pharmaceutical R&D Award. UBP also won the Gold Prize of the Taipei Biotech Award for its innovative R&D, and was selected as a Flagship Project and a Cross-Strait Pilot Program of Pharmaceutical Collaborative Development by the Taiwan FDA. UBP’s achievement in R&D and UB-421’s potential to treat AIDS have been repeatedly recognized.
United BioPharma Forward-Looking Statements
The information in this press release should be considered accurate only as of the date of the release. UBP has no intention of updating and specifically disclaims any duty to update the information in this press release. The press release may contain forward-looking statements involving risks and uncertainties and UBP’s actual results may differ materially from those in the forward-looking statements.